Zacks Investment Research upgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a sell rating to a hold rating in a report released on Wednesday, February 7th.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
A number of other analysts also recently commented on VBLT. ValuEngine upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Friday, February 2nd. HC Wainwright restated a buy rating and set a $11.00 price target on shares of Vascular Biogenics in a research report on Tuesday, November 21st. Finally, Chardan Capital lifted their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the stock a buy rating in a research report on Monday, November 6th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Vascular Biogenics has a consensus rating of Buy and a consensus price target of $15.67.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). equities analysts forecast that Vascular Biogenics will post -0.9 earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of the stock. IFP Advisors Inc boosted its holdings in shares of Vascular Biogenics by 339.7% during the fourth quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 15,117 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Vascular Biogenics during the third quarter worth approximately $135,000. Raymond James & Associates boosted its holdings in shares of Vascular Biogenics by 71.5% during the fourth quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 23,124 shares during the period. Alps Advisors Inc. acquired a new stake in shares of Vascular Biogenics during the fourth quarter worth approximately $234,000. Finally, ARK Investment Management LLC acquired a new stake in shares of Vascular Biogenics during the fourth quarter worth approximately $302,000. Institutional investors and hedge funds own 6.24% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2018/02/15/vascular-biogenics-vblt-upgraded-to-hold-at-zacks-investment-research.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.